Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study

David P. French a,b,*, Lorna McWilliams a,b, Anthony Howell b,c,d,e, D Gareth Evans b,c,d,f

a Manchester Centre of Health Psychology, Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Coupland Street, Manchester, M13 9PL, England, UK
b NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, England, UK
c The Nightingale and Prevent Breast Cancer Centre, Manchester University NHS Foundation Trust, Manchester, M23 9LT, England, UK
d Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, 555 Wilmslow Rd, Manchester, M20 4GJ, England, UK
e Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, England, UK
f Genomic Medicine, Division of Evolution and Genomic Sciences, The University of Manchester, St Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester, M13 9WL, England, UK

ARTICLE INFO

Keywords:
Risk stratification
Screening
Attendance
Risk communication
Breast cancer
Risk adaptation
Screening harms

ABSTRACT

Risk-stratified breast cancer screening may improve the balance of screening benefits to harms. We assess a potential new harm: reduced screening attendance in women receiving below average-risk (false reassurance) or higher-risk results (screening avoidance). Following initial screening, 26,668 women in the PROCAS study received breast cancer risk estimates, with attendance recorded for two subsequent screening rounds. First-screen attendance was slightly reduced in below-average (85.6%) but not higher-risk women, compared to other women (86.4%). Second-screen attendance increased for women at higher-risk (89.2%) but not below-average, compared to other women (78.8%). Concerns about this potential harm of risk-stratified screening therefore appear unfounded.

1. Introduction

Breast cancer screening, in common with all screening, involves harms such as false positive screening test results and overdiagnosis, as well as benefits, notably, reducing breast cancer mortality [1]. One possible means of improving the balance of benefits to harms is to stratify screening according to individual cancer risk, where women at high-risk may be offered more frequent screening and preventive therapies [2] (see Table 1).

However, risk stratified screening could introduce new potential harms [3]. Telling some women that they are at below-average risk may produce false reassurance, whereby screening is no longer deemed necessary. Conversely, telling some women that they are at high-risk may produce avoidance whereby those women no longer attend screening as it is too anxiety-provoking. We have previously reported no effects of receiving risk estimates on uptake of subsequent screening appointments relative to rates of screening attendance in those sites outside of the study period [4]. However, internationally no data have yet been reported on whether receiving risk estimates produces adverse effects on subsequent cancer screening attendance, either in lower-risk (“false reassurance”) or higher-risk (“avoidance”) women.

The present study examines this potential harm with women who were provided with risk estimates in the PROCAS (Predicting Risk Of Cancer At Screening Study) prospective cohort study [5].

2. Methods

2.1. Design

A prospective cohort study with women who attended the NHS-BSP and received breast cancer risk estimates due to participation in PROCAS. Attendance at the two subsequent rounds of the Greater Manchester NHS Breast Screening Programme (NHS-BSP) was predicted by risk category estimated.
2.2. Participants and procedure

Women were aged 46–73 years at initial consent to participate in the PROCAS study (09/2009–08/2014). Of the 127,000 women invited into the PROCAS Study, 70,000 attended screening, and 58,000 accepted the offer of risk estimation [5]. Estimates were produced by the Tyrer-Cuzick model [6], which incorporated self-reported information about family history, lifestyle and hormonal factors, as well as breast density from mammograms, and, in a sub-sample, single nucleotide polymorphisms identified via saliva samples. Women received the following 10-year risk estimates: high (>8%), moderate (5–7.99%), average (2–4.99%) or below-average (<2%).

The analysis included, a random selection of 11,300 women told they were at average/below-average and all women told they were at moderate/high risk. Women who died, did not receive risk feedback, or made NHS-BSP appointments before risk estimates were received were all excluded. Risk feedback was provided 2–4 years (2011–2016) after initial consent and provision of information to estimate breast cancer risk. For the second screen following risk assessment, only women who received risk feedback before 2015 were included. Repeat NHS-BSP attendance took place from (07/2012-03/2020), with the last mammogram before April 01, 2020. The present analysis was based on NHS-BSP records of appointments that were booked and attended, as well as attendance at enhanced screening appointments for high-risk women at the Nightingale Breast Screening Centre.

2.3. Analysis

Logistic regression was used to examine the extent to which rates of attendance at (i) first screening appointment and (ii) second screening appointment following provision of risk information, were predicted by breast cancer risk communicated.

3. Results

Of the 26,680 women eligible for the present study, 23,052 (86.4%) attended their first NHS-BSP appointment following the provision of risk information. Of the 13,139 women eligible for a second mammogram after receiving risk estimation, 10,342 (78.8%) attended.

Table 1

Rates of attendance at first and second breast cancer screening appointments, according to previously estimated breast cancer risk.

| Risk Category | Number of women eligible (first screen) | Number attended first screen (percentage of women eligible) | Number of women eligible (second screen) | Number attended second screen (percentage of women eligible) |
|---------------|-----------------------------------------|-----------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------|
| Below average | 11,293                                  | 9669 (85.6%)                                              | 5528                                    | 4339 (78.5%)                                              |
| Average       | 3368                                    | 2916 (86.6%)                                              | 1652                                    | 1327 (80.3%)                                              |
| High          | 714                                     | 623 (87.3%)                                               | 370                                     | 330 (89.2%)                                               |
| Total         | 26,668                                  | 23,052 (86.4%)                                            | 13,119                                  | 10,342 (78.8%)                                            |

4. Discussion

The present results indicate a slightly lower attendance at the next screen in women who received below average risk estimates, but no significant difference at the second screen. For women who received an estimate of high breast cancer risk, uptake was significantly increased at the second screen.

The present sample of women are a somewhat atypical group in terms of attendance, as they all initially attended the NHS-BSP to be eligible for the PROCAS study (70% of eligible women attended screening), and also as they consented to take part in the PROCAS study (38% of attendees) [4]. They are therefore likely to be more in favour of screening than the general population, who would be expected to be more ambivalent about screening. This attitudinal variable was not assessed nor were other variables often found to be linked to screening attendance such as ethnicity, due to the use of routinely collected data by the NHS-BSP. Despite this, the present sample were appropriate to address the present research question regarding screening re-attendance. Further, attendance rates were similar to a directly comparable sample of women from the Greater Manchester NHS-BSP who attended their previous mammogram and whose last screen was within the previous five years: in 2012–2013 39,058 women were invited and 32,925 (84.3%) attended [5].

The present study found “false reassurance” effects of very small magnitude, with 85.6% of women at below-average risk attending their first screen, compared to an overall sample rate of 86.4%. Similarly, there is no evidence of “avoidance”, with higher-risk women showing a much greater likelihood to attend the second screen offered (89.2% attendance). These findings of little impact on behaviour are in line with previous research [7] including a questionnaire study with PROCAS participants, which found no evidence of changing other health-related behaviours according to risk estimate received [8].

There is no reason to expect a major reduction in NHS-BSP attendance for groups of women who receive either below-average or high-risk estimates. This adds to the body of evidence suggesting that many concerns about harms of risk stratified screening, such as receiving risk estimates producing anxiety are often unfounded [9].

Ethics approval and consent to participate

The present research was approved by Liverpool East NHS Research Ethics Committee [14/NW/1445]. All participants gave written informed consent for their data to be used in the present publication as part of the PROCAS study. The study was performed in accordance with the Declaration of Helsinki.

Consent for publication

All participants gave written informed consent for their data to be used.
Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to including information that could potentially allow individuals to be identified, but are available from the corresponding author on reasonable request.

Funding

This article presents independent research funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme, reference numbers RP-PG-0707-10,031: “Improvement in risk prediction, early detection and prevention of breast cancer” and Ref: RP-PG-1214-20,016: “Providing breast cancer risk information as part of national breast cancer screening programme: building an evidence base on benefits and harms to inform a decision to implement (PROCAS2).” All authors are supported by the NIHR Biomedical Research Centre in Manchester (IS-BRC-1215-20,007). The views expressed are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care.

Authors’ contributions

David P French conceived this add-on to the main PROCAS study, and all authors contributed to the study design. Funding was acquired by D Gareth Evans as part of larger programmes of work. D Gareth Evans organised the study and oversaw data extraction from the relevant datasets. David P French conducted all analyses. David P French drafted the manuscript, and all authors contributed towards interpretation of data and writing and review of the manuscript. All authors have read and approved the final version of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Declaration of competing interest

The authors declare they have no competing interests.

Acknowledgements

We are grateful to the women who participated in the present research, and to the assistance of the PROCAS administration team, particularly Jake Southworth.

References

[1] Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778–86.
[2] Pashayan N, Antoniou A, Ivanus U, et al. Personalised early detection and prevention of breast cancer: ENVISION Network Consensus Statement. Nat Rev Clin Oncol 2020;17:687–705.
[3] French DP, Howell A, Evans DG. Psychosocial issues of a population approach to high genetic risk identification: behavioural, emotional and informed choice issues. Breast 2018;37:148–53.
[4] Evans DGR, Donnelly LS, Harkness EF, et al. Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer 2016;114:1045–52.
[5] Evans DG, Astley SM, Stavrinos P, et al. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinic: a dual cohort studyvol. 4. Southampton (UK): NIHR Journals Library; Aug (Programme Grants for Applied Research; 2016. p. 11.
[6] Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23(7):1111–30.
[7] Cooper GC, Harvie MN, French DP. Do negative screening test results cause false reassurance? A systematic review. Br J Health Psychol 2017;22:958–77.
[8] French DP, Southworth J, Howell A, et al. Psychological impact of providing women with personalized ten-year breast cancer risk estimates. Br J Cancer 2018;118:1648–57.
[9] French DP, Astley S, Brentnall AR, et al. What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomized comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer 2020;20:570.